Endocrine Society Announces Departure of CEO Kate Fryer

The Endocrine Society has announced the departure of CEO Kate Fryer, CAE, effective June 5, 2026. Fryer had served in the role since 2021.

“On behalf of the Board of Directors, I want to thank Kate for her contributions during her tenure,” said Carol Lange, PhD, President of the Endocrine Society Board of Directors (Board). “As we enter our next phase of growth, the Board will be seeking leadership to drive our strategic objectives as we unite, lead, and grow the endocrine community to accelerate scientific breakthroughs and improve health worldwide.”

Under Fryer’s leadership, the operating revenue grew more than 10% and the investment portfolio by almost 20%; a new journal—JCEM Case Reports—was launched; a suite of new programs, products, and services were begun that are focused on serving basic scientists, including a partnership with Keystone for boutique conferences; and the Hormone Foundation was re-envisioned. Additionally, under her oversight, the Society merged with the Association of Program Directors in Endocrinology, Diabetes and Metabolism (APDEM).

The Board will engage in a formal search process for a Chief Executive Officer.

About the Endocrine Society
Endocrinologists are at the core of solving the most pressing health problems of our time, including diabetes, obesity, infertility, bone health, and hormone-related cancers. The Endocrine Society is the largest global organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

With more than 18,000 members in 133 countries, the Society serves as the voice of the endocrine field. Through its renowned journals and ENDO, the world's largest endocrine meeting, the Society accelerates hormone research, advances clinical excellence in endocrinology, and advocates for evidence-based policies on behalf of  the global endocrine community. To learn more, visit our online newsroom.